Skip to main content

Table 5 The nine questions for which the proportion of answers differed significantly between the panelists and the SBM affiliated breast surgeons

From: Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology

Questions

Groups

p-value*

Panelists before brainstorming

n (%)

Affiliated breast surgeons

n (%)

Q09. Following BCS and when the SLN is affected at upfront surgery, in addition to systemic treatment would you recommend:

 Axillary dissection?

1 (3.7)

47 (22.0)a

0.02

 Watchful waiting?

4 (14.8)a

11 (5.1)

 

 Radiotherapy?

22 (81.5)

156 (72.9)

 

Q10. In a patient submitted to mastectomy with positive SLN at upfront surgery, in addition to systemic treatment what would you recommend:

 Axillary dissection?

4 (14.8)

86 (40.2)

0.03

 Watchful waiting?

1 (3.7)

9 (4.2)

 

 Radiotherapy?

22 (81.5)

119 (55.6)

 

Q20. In T1/2 N0 patients submitted to mastectomy, evaluation of flap thickness using imaging should be recommended following surgery.

 I agree

2 (7.4)

68 (31.8)

0.01

 I disagree

25 (92.6)

146 (68.2)

 

Q24. In T1/2 N1 patients submitted to mastectomy who have achieved pCR following neoadjuvant treatment, radiotherapy of the thoracic wall should be recommended.

 I agree

27 (100.0)

140 (65.4)

0.01

 I disagree

0 (0.0)

74 (34.6)

 

Q36. In patients with the BRCA germline mutation, the use of platinum agents in neoadjuvant treatment should be recommended.

 I agree

16 (59.3)

175 (81.8)

0.01

 I disagree

11 (40.7)

39 (18.2)

 

Q37. In patients who will be submitted to neoadjuvant treatment, the addition of immunotherapy should be recommended as routine.

 I agree

14 (51.9)

65 (30.4)

0.02

 I disagree

13 (48.1)

149 (69.6)

 

Q38. In patients who will be submitted to neoadjuvant treatment, PD-L1 status should be taken into consideration when recommending immunotherapy.

 I agree

13 (48.1)

151 (70.6)

0.02

 I disagree

14 (51.9)

63 (29.4)

 

Q39. BRCA status should play a role in the decision regarding whether to recommend neoadjuvant treatment with immunotherapy.

 I agree

5 (18.5)

94 (43.9)

0.01

 I disagree

22 (81.5)

120 (56.1)

 

Q43. In patients with no BRCA germline mutation submitted to neoadjuvant therapy with immunotherapy and in whom there is residual disease, the use of adjuvant immunotherapy associated with capecitabine should be suggested.

 I agree

14 (51.9)

160 (74.8)

0.01

 I disagree

13 (48.1)

54 (25.2)

 
  1. SBM Brazilian Society of Mastology, BCS breast-conserving surgery, SLN sentinel lymph node, pCR pathologic complete response
  2. *Chi-square test; aPost hoc; n = absolute frequency; % = relative frequency